skip to Main Content

Quality of Life Data for PARP Inhibitor Shows Promise for Pancreatic Cancer Treatment

Newsfeed image, light gray text on dark gray background
The PARP inhibitor olaparib (Lynparza) significantly delayed progression of disease in patients with metastatic pancreatic cancer who also harbored a germline BRCA gene mutation, according to study findings presented during the European Society of Medical Oncology 2019 Annual Congress.

Back To Top